It's Not Cholesterol. Inflammation Is What's Actually Causing Heart Disease

Cindy Guyer explains that LDL quality matters: pattern A (large fluffy) is relatively benign, while pattern B (small dense) is highly atherogenic. Mark Hyman presents a case of an 84‑year‑old man with LDL 160 — a “great” number — but particle number 1,500 (should be <1,000) and small LDL 900 (should be <300). This patient, who was thin and pre‑diabetic, had early dementia and would have been missed by standard care. Cindy adds that remnant particles (VLDL, IDL) are also hidden. Both experts insist that the NMR/Cardio IQ test should be standard; the delay in uptake is because medicine treats what it can easily measure and there’s no pill for small dense LDL. Addressing the root — insulin resistance — can dramatically improve the particle profile.

Mark Hyman recounts a woman with severe central obesity and high cardiovascular risk whose fasting glucose, A1c, and OGTT glucose were pristine. Yet her fasting insulin was 50 (normal <5) and post‑drink peaked at 250. Her hyperinsulinemia was driving relentless hunger, fat accumulation, and inflammation. Once she eliminated starch and sugar, she lost 50 lbs and her risk profile normalized. Cindy Guyer adds that this insulin pattern correlates tightly with the small dense LDL, fatty liver, and neuropathy, all occurring before hyperglycemia. Mark cites the Quest lab director saying <1% of orders include insulin, illustrating the systemic blind spot. The protocol is to test, detect, and then treat the insulin resistance with carbohydrate restriction.

Cindy Guyer presents the statistic that 80% of heart disease and diabetes can be prevented through diet and lifestyle, yet fewer than 3% of Americans meet these four factors — a shockingly low bar. Mark Hyman notes that our society is structured to cause heart disease, with chronic stress, loneliness, and sleep deprivation acting as silent drivers. The protocol is deceptively simple: no smoking, moderate activity, whole foods, and healthy weight. But because the medical system reinforces a pill‑for‑every‑ill model, these foundations are neglected. The message is that individual agency exists, but it requires consciously fighting the environmental forces pushing in the opposite direction.

Eric Topol describes the full stack: simple lipids plus ApoB and Lp(a) are the foundation. Adding an inexpensive polygenic risk score and a ‘heart clock’ provides a lifetime risk picture. For those flagged, retinal AI can predict Alzheimer’s and stroke, while CT angiography with Caristo’s AI sees inflammation in the absence of stenosis — carrying a 15‑fold heart attack risk. He says this allows us to ‘stamp out inflammation’ and aggressively lower LDL with PCSK9 inhibitors and upcoming LP(a)‑lowering drugs, while GLP‑1 agonists reduce inflammation before weight loss. This precision cardiology transforms heart disease from an inevitable fate into an optional condition, provided we screen early.

Cindy Guyer reminds us that 21 years ago, Libby and Ridker established the inflammatory nature of heart disease, yet the standard response is aspirin and statins without addressing upstream causes like stress, poor sleep, and loneliness. Eric Topol later notes that we now have the means to ‘stamp out inflammation’ — GLP‑1 drugs, which have been shown to prevent heart failure with preserved ejection fraction (half of all heart failure) and reduce events in diabetics and non‑diabetics, seem to do so largely via inflammation reduction before any weight loss occurs. Combined with lifestyle and the new diagnostic tools, this creates a unified strategy: measure inflammation, remove its sources, and pharmacologically quench it when high.

Dr. Cindy Guyer recalls the pivotal New England Journal of Medicine review in 2000 by Peter Libby and Paul Ridker that demonstrated cardiovascular disease is driven by ongoing inflammation. She notes that President Bush’s doctors measured his CRP but didn’t know what to do about it, epitomizing the clinical void. Mark Hyman reinforces that heart disease is “not a plumbing problem — it’s an immune problem.” The duo emphasize that inflammation itself is a symptom with many upstream drivers: stress, poor sleep, loneliness, infections, toxins, and insulin resistance. Yet the medical system defaults to a poly‑pill (aspirin, statin, blood pressure drug) instead of exploring these root causes. The segment challenges the audience to see heart disease as a result of systemic inflammation that can be quelled by lifestyle changes and addressing hidden insults.

Cindy Guyer cites the 2009‑2016 NHANES data showing that meeting optimal thresholds for blood pressure, HDL, triglycerides, and glucose classifies only 12.2% of Americans as metabolically healthy. Strikingly, fewer than one‑third of normal‑weight people met those criteria, meaning two‑thirds of “skinny” people are metabolically unhealthy and at risk. Mark Hyman extrapolates that practically nine out of ten Americans have some degree of pre‑diabetes or type 2 diabetes when insulin is considered, but doctors fail to test for it. This metabolic crisis drives heart disease independent of cholesterol, yet the healthcare system is built around treating end‑stage manifestations (high glucose, high LDL) with drugs rather than early detection of insulin resistance. The message: weight and basic labs are misleading, and metabolic dysfunction is rampant, preventable, and reversible.

Mark Hyman vividly describes a patient with central obesity, high blood pressure, and high cardiovascular risk. Her fasting glucose, OGTT glucose, and A1c were perfect, but her fasting insulin was 50 (optimal <5) and after a glucose drink it soared to 250. Her body was pouring out insulin to keep glucose normal, creating a state of starvation at the cellular level — driving hunger, fat storage in visceral adipocytes, and systemic inflammation. Cindy Guyer points out that this hyperinsulinemic pattern is tightly linked to the small dense LDL profile, fatty liver, and neuropathy, all occurring while glucose remains normal. Mark cites the Quest lab director’s statistic that fewer than 1% of labs measure insulin, illustrating how completely the system overlooks this. The takeaway is that cardiovascular disease is fundamentally a hormonal and inflammatory problem rooted in insulin resistance, and early detection requires looking at insulin, not just sugar.

Malhotra recounts how questioning the low‑fat obesity epidemic led him to investigate the cholesterol hypothesis. His 2013 BMJ piece “saturated fat is not the major issue” met backlash but proved prescient. He digs into Framingham: William Castelli, co‑director, found that unless LDL exceeded ~250 mg/dL, it was useless as a predictor after accounting for triglycerides and HDL. Then Malhotra and two other cardiologists systematically reviewed every randomized controlled drug trial — statins and PCSK9 inhibitors — and found no consistent relationship between how much LDL was lowered and cardiovascular event reduction, even in high‑risk patients. He further notes that in people over 60, observational data show an inverse association between LDL and all‑cause mortality, likely because cholesterol is vital for immunity, hormone production, and cell membranes. The editorial “saturated fat does not clog the arteries” in 2017, co‑authored with editors of JAMA Internal Medicine and BMJ Open, encapsulated the message: coronary disease is a chronic inflammatory condition, not a lipid storage disease.

Dr. Eric Topol outlines a layered risk assessment: start with a simple lipid panel plus Lp(a) and ApoB at least once, add an inexpensive polygenic risk score, and incorporate a “heart clock” along with inflammation markers. For those flagged as high risk, retinal AI exams can predict Alzheimer’s and cardiovascular events through fundus photography. Even more powerful, CT angiography with a new AI analysis of the fat surrounding coronaries (Caristo, an Oxford spin‑out) can detect inflammation without stenosis – a finding that confers a 15‑fold risk of heart attack. He advocates aggressive LDL lowering in such patients, targeting <30 mg/dL, using PCSK9 inhibitors and forthcoming Lp(a) drugs. GLP‑1 agonists reduce inflammation before weight loss and prevent heart failure with preserved ejection fraction. Topol stresses that lifestyle remains foundational, but these tools give unprecedented agency to prevent the #1 killer.